The traditional HR Business Partner (HRBP) model, once the gold standard for HR delivery, is undergoing a significant transformation. Many organizations, particularly in industries like pharmaceuticals, are moving towards a more agile resource model, aiming to streamline HR operations and…
HOME > ARCHIVE
ARCHIVE
- Bayer to Accumulate Medicoeconomic Evidence
June 20, 2011
- MediBIC: Glufosfamide Granted Orphan Drug Status in Europe
June 20, 2011
- Korosho to Preferentially Support High-Quality Clinical Research
June 20, 2011
- ASKA Spreading Risks in Production, Distribution to Ensure Stable Supplies
June 20, 2011
- Korosho Calls For Development of 3 Drugs Used Off-label
June 20, 2011
- Reform Council Sees ¥1.6 Tril. Increase in Healthcare/Nursing Expenditure in FY2015
June 20, 2011
- Top-3 Dispensing Pharmacy Chains Report Record-high Sales, Profits Driven by New Store Openings
June 20, 2011
- Infections Added as Serious ADE for Revlimid: Safety Info.
June 20, 2011
- Korosho's Expert Committee Proposes Creation of “Pediatric Cancer Hub Hospitals”
June 20, 2011
- Major Drugstore Chains Report Increased Sales in Dispensing Business
June 20, 2011
- Top-4 Generic Makers Report Double-digit Growth in Sales, Profits
June 20, 2011
- Korosho to Permit Telemarketing of OTC Drugs to Residents of Isolated Islands for 2 More Years
June 20, 2011
- Ain Pharmaciez Posts New Record-high Sales
June 20, 2011
- Sawai: Sales, Profits Up Driven by Good Sales to Pharmacies
June 20, 2011
- Takeda Launches Sonias Combination Tablet for Type 2 Diabetes
June 20, 2011
- Sales Down 5.8% for Ethical Drugs in April: Crecon Research & Consulting
June 20, 2011
- Towa: Double-digit Growth in Both Sales, Profits
June 20, 2011
- PAFSC Committee Turns Down Approval of Epogin for Anemia in Cancer Patients
June 20, 2011
- PMDA Should Develop Better Assessment Methods with Industry: Korosho Councilor Hirayama
June 20, 2011
- New Prescription of Actos Suspended in France, Germany due to Bladder Cancer Risk
June 20, 2011
ページ
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…